Orphan designation: telisotuzumab adizutecan Treatment of pancreatic cancer, 25/03/2026 Positive | European Federation of Internal Medicine

Submitted by Anonymous (not verified) on 22 April 2026 - 9:50

Orphan designation: telisotuzumab adizutecan Treatment of pancreatic cancer, 25/03/2026 Positive

Link:

https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-26-3213

Source:

Newsletters

Stay informed on our latest news!

Latest Newsletters